As UGCG has emerged as a key therapeutic target, we targeted the inhibition of UGCG using the FDA-approved UGCG inhibitor Eliglustat in MCF-7 and BT-474 tumor models upon intraperitoneal delivery. This evidence concerns the gene UGCG and neoplasm.